Immunosuppressant for treating T-cell-mediated inflammatory diseases
This technology is an immunosuppressant that suppresses T cell proliferation and can be used to treat organ transplant rejection, autoimmune or inflammatory conditions, and modulate the immune and bone microenvironment of multiple myeloma.
Unmet Need: Immunosuppressant that inhibits T cell expansion in transplant and immune-mediated diseases
T cell proliferation can cause complications with organ transplantation and contribute to autoimmune and inflammatory disease pathology. The immunosuppressant market is growing rapidly, and there is ongoing need for therapeutics that demonstrate long-term slowing of disease progression.
The Technology: Suppressor of T cell expansion in inflammatory diseases
This technology uses peptide fragments derived from matrix metalloproteinase-13 (MMP-13) to modulate immune activity by suppressing T-cell proliferation. These immunosuppressive effects are independent of the enzyme’s catalytic domain. MMP-13 can treat multiple myeloma (MM) bone disease and modulate the MM immune environment by targeting PD-1H–mediated osteoclast activation, which contributes to bone resorption and immune dysregulation.
This technology has been validated in both in vitro and in vivo models of T cell proliferation inhibition.
Applications:
- Prevention of transplant/graft rejection
- Treatment for autoimmune and inflammatory disorders
- Immunostimulant to treat cancer or infections
- Research tool for studying T cell proliferation
- Treatment for multiple myeloma bone disease
Advantages:
- Can enhance immune function with a blocking antibody or small molecule
- Immune suppression does not require the enzyme catalytic domain
- Endogenously present in the human body
- Applicable to many diseases
- Uses a small peptide rather than a large antibody
Lead Inventor:
Patent Information:
Patent Pending(US 18/310,702)
Related Publications:
Tech Ventures Reference:
IR CU21025
Licensing Contact: Jerry Kokoshka